Can I Take 5-HTP with Dayvigo (Lemborexant)?

How Dayvigo Works: Orexin Receptor Antagonism

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance [1]. It blocks both OX1R and OX2R receptors, suppressing the wake-promoting orexin signaling system rather than broadly sedating the central nervous system.

Orexin Pathways vs. Serotonin Pathways

Orexin neurons originate in the lateral hypothalamus and project widely across the brain, including to serotonergic neurons in the dorsal raphe nucleus [2]. Blocking orexin signaling reduces wake drive. This is mechanistically distinct from drugs that enhance GABA (benzodiazepines, Z-drugs) or modulate serotonin. Lemborexant does not bind serotonin receptors, serotonin transporters, or monoamine oxidase enzymes.

Clinical Efficacy Data

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg both reduced latency to persistent sleep and wake after sleep onset compared to placebo over 30 nights in adults aged 55 and older [3]. The SUNRISE-2 trial (N=949) confirmed sustained efficacy over 12 months at both doses, with no evidence of rebound insomnia on discontinuation [4].

How 5-HTP Works: Serotonin Precursor Loading

5-Hydroxytryptophan (5-HTP) is an amino acid intermediate in the biosynthesis of serotonin. It is produced naturally from tryptophan by the enzyme tryptophan hydroxylase, then converted to serotonin (5-HT) by aromatic L-amino acid decarboxylase (AADC). Oral 5-HTP supplements bypass the rate-limiting tryptophan hydroxylase step, delivering substrate directly to AADC in both the gut and brain [5].

Serotonin's Role in Sleep

Serotonin has a complex, bidirectional relationship with sleep. The dorsal raphe serotonergic neurons are most active during wakefulness and fall silent during REM sleep [6]. Serotonin is also the metabolic precursor to melatonin through N-acetylation and O-methylation in the pineal gland. Some users take 5-HTP to promote sleep onset by increasing melatonin substrate availability, though clinical trial evidence for this indication remains limited. A small crossover study (N=18) suggested 5-HTP at 200 mg increased REM sleep latency and total REM duration compared to placebo, but the sample size limits generalizability [7].

Typical Supplement Doses

5-HTP is sold as an over-the-counter supplement, most commonly in 50 mg, 100 mg, and 200 mg capsules. Doses used in published studies range from 150 mg to 800 mg daily, though most clinicians who recommend it keep doses at or below 300 mg/day [5].

Is There a Direct Pharmacokinetic Interaction?

No clinically significant pharmacokinetic interaction between lemborexant and 5-HTP has been identified in the published literature.

Lemborexant Metabolism

Lemborexant is primarily metabolized by CYP3A4, with minor contributions from CYP3A5 [1]. Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) increase lemborexant exposure and require dose adjustments or avoidance per the FDA label. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) substantially reduce lemborexant plasma levels and are listed as a contraindication.

5-HTP and CYP Enzymes

5-HTP is not a known inhibitor or inducer of CYP3A4, CYP2D6, CYP1A2, or other major drug-metabolizing enzymes. It is rapidly decarboxylated to serotonin by AADC, a pyridoxal phosphate-dependent enzyme, rather than processed through cytochrome P450 pathways [5]. This means 5-HTP should not alter Dayvigo blood levels, and Dayvigo should not alter 5-HTP conversion rates. The interaction concern here is pharmacodynamic, not pharmacokinetic.

The Pharmacodynamic Concern: Serotonin Syndrome

The primary risk flag for combining 5-HTP with any prescription medication is serotonin syndrome, a potentially life-threatening condition caused by excess serotonergic activity in the central and peripheral nervous systems.

What Serotonin Syndrome Looks Like

The Hunter Serotonin Toxicity Criteria define the diagnosis by the presence of a serotonergic agent plus one of these clinical features: spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with temperature above 38°C and clonus [8]. Mild cases present as tremor, diarrhea, and restlessness. Severe cases can include hyperthermia above 41°C, seizures, rhabdomyolysis, and cardiovascular collapse.

Dayvigo Alone Does Not Raise Serotonin

Lemborexant does not increase synaptic serotonin concentrations. It does not inhibit serotonin reuptake, inhibit monoamine oxidase, or directly stimulate serotonin receptors. The FDA prescribing information for Dayvigo does not list serotonin syndrome among its warnings or precautions [1]. When the only two agents on board are Dayvigo and 5-HTP, the serotonin load comes exclusively from the 5-HTP. At typical supplement doses (100 to 200 mg), 5-HTP alone has a low probability of causing serotonin syndrome in otherwise healthy adults [5].

The Risk Multiplier: Concurrent Serotonergic Drugs

The risk equation changes substantially when a third serotonergic agent is present. A 2022 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that serotonin syndrome reports were disproportionately associated with combinations of serotonin precursors (tryptophan, 5-HTP) and SSRIs or SNRIs, rather than with precursors alone [9]. If you take sertraline, fluoxetine, venlafaxine, duloxetine, or another serotonergic antidepressant alongside Dayvigo and 5-HTP, the combination creates a clinically meaningful serotonin syndrome risk.

Additive CNS Depression: A Separate Concern

Beyond serotonin, there is a second pharmacodynamic interaction worth noting: additive central nervous system (CNS) depression.

Dayvigo and Sedation

The Dayvigo label carries a warning about CNS depressant effects, advising against co-administration with alcohol and recommending caution with other CNS depressants [1]. The most common adverse reaction in clinical trials was somnolence, reported in 10% of patients on lemborexant 10 mg vs. 1% on placebo in SUNRISE-2 [4].

5-HTP and Drowsiness

5-HTP can cause drowsiness, particularly at doses above 200 mg. This effect is partly mediated by serotonin's conversion to melatonin and partly by serotonin's own sedative properties at certain receptor subtypes (5-HT1A activation in the raphe) [6]. Taking 5-HTP at bedtime alongside Dayvigo could amplify sedation, which may sound desirable for an insomnia patient but increases the risk of next-morning impairment, falls, and impaired driving.

Practical Implications

If excessive daytime somnolence develops after adding 5-HTP to a Dayvigo regimen, the combination may impair work performance and driving safety. The FDA requires the Dayvigo label to note that patients should be cautioned about operating heavy machinery or driving until they know how the drug affects them [1]. Adding a sedative supplement amplifies this concern.

Dose-Separation and Timing Strategies

No published clinical study has tested a specific dose-separation window between lemborexant and 5-HTP. The following guidance is extrapolated from the pharmacokinetic profiles of each agent.

Lemborexant Pharmacokinetics

Lemborexant reaches peak plasma concentration (Tmax) approximately 1 to 3 hours after oral administration. Its elimination half-life is roughly 17 to 19 hours [1]. It is taken once nightly, within minutes of going to bed.

5-HTP Pharmacokinetics

Oral 5-HTP is rapidly absorbed, with peak plasma levels occurring within 1 to 2 hours. Its plasma half-life is approximately 4 to 6 hours, but its pharmacodynamic effects on brain serotonin may persist longer because newly synthesized serotonin is stored in vesicles [5].

A Reasonable Approach

If a clinician approves the combination, taking 5-HTP in the early evening (e.g., 4 to 6 hours before Dayvigo) could reduce the peak-on-peak overlap between the two agents' CNS effects. This does not eliminate the pharmacodynamic interaction but may moderate the acute additive sedation at bedtime. There is no published evidence that this specific window is protective. It is a clinical judgment call, not a guideline recommendation.

Monitoring if You Are Already Taking Both

Some patients will arrive at their clinician's office already taking 5-HTP and Dayvigo together. Abruptly stopping either agent without guidance is not recommended.

What to Watch For

Serotonin-related warning signs include muscle twitching or jerking (myoclonus), profuse sweating not explained by ambient temperature, rapid heart rate, agitation or restlessness, diarrhea, and dilated pupils. These symptoms warrant immediate medical evaluation.

CNS depression warning signs include difficulty waking in the morning, impaired concentration lasting more than 2 hours after waking, unsteady gait, and any near-miss or actual fall.

Clinician Checklist

Prescribers should review the full medication and supplement list. The critical question is whether a third serotonergic agent (SSRI, SNRI, tramadol, triptans, MAOIs, St. John's wort) is also on board. If yes, the 5-HTP should generally be discontinued. If Dayvigo and 5-HTP are the only two agents, the risk is lower but monitoring should continue, especially in the first two weeks after initiation or dose change.

Who Should Avoid This Combination Entirely

Certain populations face outsized risk from this combination and should not take 5-HTP with Dayvigo without explicit specialist guidance.

Patients on SSRIs or SNRIs

As discussed, adding 5-HTP to a regimen that already includes an SSRI or SNRI and Dayvigo creates a three-agent serotonergic stack. The FAERS data show that serotonin precursors combined with reuptake inhibitors carry the highest reporting odds ratio for serotonin syndrome among supplement-drug pairs [9].

Patients with Hepatic Impairment

Lemborexant exposure increases in patients with mild or moderate hepatic impairment. The FDA recommends a maximum dose of 5 mg in moderate hepatic impairment and does not recommend use in severe hepatic impairment [1]. Adding any agent that increases CNS depression to an already-elevated lemborexant exposure is inadvisable without close monitoring.

Older Adults at Fall Risk

The SUNRISE-1 trial enrolled adults 55 and older and did not find a statistically significant increase in falls with lemborexant vs. Placebo [3]. Adding a sedative supplement to this population, particularly in those with baseline gait instability or polypharmacy, could shift that risk profile.

Alternatives to 5-HTP for Sleep Support Alongside Dayvigo

Patients interested in non-prescription sleep support while taking Dayvigo have options with less pharmacodynamic overlap.

Sleep hygiene measures remain the foundation of insomnia management. The American Academy of Sleep Medicine (AASM) recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with or without pharmacotherapy [10]. Melatonin at doses of 0.5 mg to 3 mg, taken 1 to 2 hours before desired sleep onset, works through MT1/MT2 receptors and does not raise serotonin concentrations [11]. Magnesium glycinate (200 to 400 mg at bedtime) has modest evidence for improving subjective sleep quality without serotonergic or significant CNS depressant effects [12]. These alternatives avoid stacking serotonin precursors on top of an orexin antagonist.

The Bottom Line

Dayvigo and 5-HTP act through different primary mechanisms (orexin antagonism vs. Serotonin precursor loading), and there is no pharmacokinetic interaction between them. The risk of serotonin syndrome from these two agents alone is low. That risk rises sharply if an SSRI, SNRI, or other serotonergic drug is also present. Additive sedation is the more likely adverse outcome in a two-drug scenario and should be monitored with attention to next-morning impairment. Do not start or stop either agent without discussing the combination with your prescriber, and keep your clinician informed of every supplement you take. The Endocrine Society and the AASM both recommend full supplement disclosure during medication reconciliation [10].